Table 1 Patient characteristics and baseline data

Age, Mean ± SD

63.87 ± 5.87

63.14 ± 7.54

0.641

Sex, n (%)

0.914

 Male

27(90)

38(86.4)

 Female

3(10)

6(13.6)

Smoking status, n (%)

0.982

 Never

7(23.3)

11(25)

 Former

6(20)

9(20.5)

 Current

17(56.7)

24(54.5)

Smoking index, Median(range)

35(0–150)

30(0–90)

0.405

ECOG PS score, n (%)

0.058

 0

9(30)

23(52.3)

 1

21(70)

21(47.7)

Histology, n (%)

0.815

 Squamous cell carcinoma

26(86.7)

36(81.8)

 Non -squamous cell carcinoma

4(13.3)

8(18.2)

cTNM Stage, n (%)

0.135

 IA

1(3.3)

0(0)

 IB

5(16.7)

4(9.1)

 IIA

2(6.7)

0(0)

 IIB

5(16.7)

9(20.5)

 IIIA

11(36.7)

26(59.1)

 IIIB

6(20)

5(11.4)

cT stage, n (%)

0.941

 cT1

5(16.7)

6(14)

 cT2

15(50)

22(50.0)

 cT3

6(20)

8(18.6)

 cT4

4(13.3)

8(18.6)

cN stage, n (%)

0.301

 cN0

13(44.8)

12(27.3)

 cN1

3(10.3)

8(18.6)

 cN2

14(46.7)

24(55.8)

GOLD grade, n (%)

 I

8(26.7)

-

 II

21(70)

 III

1(3.3)

-

Neoadjuvant cycle, n (%)

0.369

 1 cycle

1(3.3)

0(0)

 2 cycle

17(56.7)

25(56.8)

 3 cycle

12(40)

16(36.4)

 4cycle

0(0)

3(6.8)

Treatment regimens, n (%)

0.978

 PD-L1 + chemotherapy

5(16.7)

6(13.6)

 PD-1 + chemotherapy

25(83.3)

38(86.4)

Adjuvant cycle, n (%)

0.966

  ≤ 6 cycle

21(70)

31(70.5)

  > 6 cycle

9(30)

13(29.5)